Table 4_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.doc by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Table 2_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.doc by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Image 6_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.tif by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Image 7_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.tif by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Image 1_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.tif by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Image 8_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.tif by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Image 5_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.tif by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Image 4_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.tif by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Image 3_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.tif by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Image 2_First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.tif by Zhifang Mao (22643888)

“…Background<p>PD-1/PD-L1 inhibitors plus chemotherapy (PC) are now broadly acknowledged as effective for treating stage IIIb–IV non-small cell lung cancer (NSCLC). However, data specific to Asian populations remain limited, and updated evidence from randomized controlled trials (RCTs) is warranted. …”

Figure 5 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells by Stacia L. Koppenhafer (16616290)

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic N... by Xinhang Gu (22686224)

“…Background<p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-based combination therapy modalities for patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC) are being investigated. …”

High-throughput 16S rRNA gene sequencing reveals alterations of mouse intestinal microbiota after radiotherapy by Soo-Je Park (14634305)

“…Unexpectedly, irradiation treatment increased the number of <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/operational-taxonomic-unit" target="_blank">operational taxonomic units</a> in the small intestine but not the large intestine. …”

Development of an Intravenously Stable Disulfide-Rich Peptide for the Treatment of Chemotherapy-Induced Neuropathic Pain by Tianmiao Li (19796984)

Subjects:

Further validation of alisertib in HEK293T cells relating to CRISPR gene editing outcomes. by Danny Wilbie (14050812)

Subjects:

Gene editing efficacies and cytotoxicity on Hepa 1-6 eGFP pretreated with aurora kinase inhibitors alisertib, danusertib or PF-03814735 using ProdeliverIN CRISPR for RNP delivery. by Danny Wilbie (14050812)

Subjects:

Hit validation of the findings in Fig 1. by Danny Wilbie (14050812)

Subjects:

Selected compounds and their respective IC50 in HEK293T-eGFP cells after 3 days of incubation. The dosage schemes in the gene-editing screening experiment were based on these IC50... by Danny Wilbie (14050812)

Subjects:

Initial screening performed using oncological compounds on CRISPR genome editing outcomes. by Danny Wilbie (14050812)

Subjects:

Development of an Intravenously Stable Disulfide-Rich Peptide for the Treatment of Chemotherapy-Induced Neuropathic Pain by Tianmiao Li (19796984)

Subjects: